Interestingly, in STAD patients that experienced progression after receiving adjuvant or neoadjuvant chemotherapy, the H19 level was an even more significant indicator for DSS, with a HR of 2.15 (1.16–4.00) (Figure 1(h)). This evidence concerns the gene H19 and gastric adenocarcinoma.